Digital transformation and HPE’s strategic partnerships to be spotlighted during April 21 event
SHARE
If failure is not an option for most organizations, then why is it that digital transformation fails to meet objectives 70% of the time?
Research by McKinsey & Co. in 2019 documented this failure rate, a number that was more recently confirmed by Boston Consulting Group. This question has become more central in the minds of a number of CEOs as a global pandemic has accelerated the pace of digital change for many firms. Now, 80% of senior executives indicate they intend to accelerate digital transformation efforts.
How an organization uses technology, people and processes to reshape business operations and models has proven to be far from easy. Yet, it remains the number one topic in the information technology world, and major technology players are ready to provide advice and solutions.
First patient-derived organoid model for cervical cancer eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
Arix Bioscience PLC: Artios announces collaboration with Novartis to create next generation DDR cancer therapies
DJ Artios announces collaboration with Novartis to create next generation DDR cancer therapies
Arix Bioscience PLC (ARIX)
Artios announces collaboration with Novartis to create next generation DDR cancer therapies
07-Apr-2021 / 07:00 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=
Arix Bioscience plc
Artios announces collaboration with Novartis to create next generation DDR cancer therapies - Artios to receive USD20 million up-front payment in addition to near term research funding to support the
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Artios Pharma Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies
Artios Pharma, Inc.April 7, 2021 GMT
Novartis to leverage Artios’ discovery platform to identify DDR targets for use with Novartis’ proprietary radioligand therapies.
Artios to receive US$20 million up-front payment in addition to near term research funding to support the collaboration.
Artios eligible to receive up to $1.3 billion in discovery, development, regulatory and sales-based milestones in addition to royalty payments.
CAMBRIDGE, United Kingdom and NEW YORK, April 07, 2021 (GLOBE NEWSWIRE) Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company exploiting synthetic lethality to develop a broad pipeline of precision medicines for the treatment of cancer, today announced a global research collaboration with Novartis to discover and validate next generatio
Scientists use cryo-electron microscopy to unravel how guardian of the genome works news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.